Over 15 years as a multi-talented Clinical Research Professional managing Phase II-IV clinical trials in different therapeutic areas. Responsible for comprehensive project development and management. Experience also includes compliance according to ICH/GCPs and other regulatory agency guidelines. As well as dedicated experience in complying with study protocols, standard operating procedures. Practiced problem-solver with strong attention to detail. Proficient in handling patient information, laboratory samples, and compliance procedures for different clinical trials. Well-organized and hardworking with excellent communication and planning skills. Prepared to offer extensive experience in the field and take on a fast-paced position.
Vaccines, GI (Crohn's Disease, Ulcerative Colitis, IBS-D, IBS-C, GERD, Lactose Intolerance), Cardiovascular (Cholesterol, AFIB, HRVD), Neurology (Migraine, Parkinson's Disease), Respiratory (Asthma, COPD), | Other (Osteoarthritis, Rheumatoid Arthritis, Overactive Bladder, Insomnia), Endocrinology (Diabetes, Diabetic Neuropathy), Nephrology (CKD, Metabolic Acidosis, Dialysis). |
• A 66-Week Extension to A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
• A Phase IIb Randomized, Placebo and Active Comparator (Tolterodine) Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
• A Phase II Randomized, Placebo-controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adults with Autoimmune Disease
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Assess the Efficacy and Safety of Budesonide Foam (2MG/25ML BID for 2 Weeks, Followed by 2MG/25ML QD for 4 Weeks) Versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
• A Phase III Randomized, Double-blind, Placebo-controlled Multi-center Study of Subcutaneous Secukinumab in Pre-filled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long-Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Agents
• A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis
• DM199-2019-001, “A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients with Chronic Kidney Disease (Stage II or III)”
By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Many factors go into creating a strong resume. Here are a few tweaks that could improve the score of this resume:
resume Strength
By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy
data entry associate, quality control, research clinical coordinator
Advanced Pharma CR
Miami, Florida
clinical research data coordinator
Mayo Clinic Comprehensive Cancer Center
mesa, arizona
clinical research coordinator w/certified ophthalmic assistant
Malcolm Grow Medical Center, Joint Base
Lusby, Maryland